This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Oct 30, 2026
•
3 min read
🧬 Regeneron reports "clean sweep" Q3 with $5.1B revenue, 36% growth; key pipeline catalysts ahead, Bambusa Therapeutics prices upsized $168.9M IPO, developing bispecific antibodies for immunology, Gilead Sciences' Q3 HIV sales surge 18% to $6.2B, driving highest annual growth since 2015
Oct 29, 2026
🧬 Eli Lilly's 2026 guidance jumps $10B as GLP-1 sales, Medicare Bridge program exceed expectations, Lonza expands Swiss ADC manufacturing hub in Visp, adding mid-scale bioconjugation suites for 2028 launch, Flagship Pioneering merges Etiome, Cellarity, and Empress Therapeutics into new AI drug discovery venture Etcelera
Oct 28, 2026
🧬 Eli Lilly's (retatrutide) beats Novo's Ozempic in Ph3 trial for type 2 diabetes on blood sugar and weight loss, Biogen posts third consecutive quarter of revenue growth, reaching $2.8B with Apellis integration boost, Ferring Pharmaceuticals to acquire Gameto for up to $1.4B, adding next-gen IVF technology Fertilo
Oct 27, 2026
🧬 GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) nearly quadruples progression-free survival in Ph3 B7-H3-targeted osteosarcoma trial, Anthropic files IPO, revealing drug R&D ambitions including molecular biology lab and pharma partnerships, FDA approves Pfizer's Talzenna (talazoparib)-Xtandi (enzalutamide) combo for HRR-mutated metastatic hormone-sensitive prostate cancer based on Ph3 data
Oct 26, 2026
4 min read
🧬 Akeso, Summit Therapeutics' (ivonescimab) beats AstraZeneca's Imfinzi in Ph3 biliary tract cancer trial with 25% lower death risk, Pathos AI raises $237M Series E, led by Bristol Myers Squibb, scaling AI-driven drug development platform, Johnson & Johnson's JNJ-6143 (JNJ-6143) shows 75% overall response rate in Ph1 metastatic castration-resistant prostate cancer trial
Oct 23, 2026
🧬 Gilead Sciences acquires PepStar Therapeutics' IL-23R inhibitor program for $1.3B upfront, Alnylam plans pivotal trial for brezosiran (ALN-HTT02) targeting huntingtin protein in Huntington's disease after Ph1b success, FDA lifts clinical hold on Aardvark Therapeutics' ARD-101 after new cardiac safety data clears concerns
Oct 22, 2026
🧬 Roche's Vabysmo hits $1.38B quarterly sales, meets analyst expectations after prolonged growth slowdown, AstraZeneca's Ultomiris (ravulizumab) wins FDA accelerated approval for immunoglobulin A nephropathy, its fifth indication, FDA accepts Biohaven's Vyglxia (troriluzole) resubmission for spinocerebellar ataxia with advisory committee meeting planned
Oct 21, 2026
🧬 GSK, Ionis Pharmaceuticals win FDA approval for Hibsago (bepirovirsen) targeting hepatitis B virus in chronic hepatitis B infection following Ph3 success, Priovant Therapeutics seeks label expansion for Lisraya (brepocitinib) after Ph3 success in non-infectious uveitis, OpenAI acquires Orchestra Bio, combining AI platforms to accelerate drug development workflows
Oct 20, 2026
🧬 GSK's Jemperli (dostarlimab) receives FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer based on Ph2 data, Eli Lilly, METiS TechBio partner on AI-driven LNP drug delivery platform, up to $1.1B milestones, Gilead Sciences' (emvistegrast) meets Ph2 primary endpoint in moderately to severely active ulcerative colitis, Ph3 planned
Oct 19, 2026
🧬 Merck KGaA acquires Silence Therapeutics for $1.3B, gaining promising siRNA blood cancer drug divesiran, Disc Medicine's (bitopertin) Ph3 trial meets all endpoints for erythropoietic protoporphyria, paving way for FDA resubmission, Sanofi breaks ground on new Frankfurt insulin manufacturing facility, targeting full production by 2032
Oct 17, 2026
Deciding which diseases are worth studying has never been a purely scientific question. It has always come down to how much evidence one person can hold in their head. AI is changing that.
Oct 16, 2026
🧬 Roche's Enspryng (satralizumab) wins FDA approval for thyroid eye disease, targeting interleukin-6 receptor following Ph3 data, City Therapeutics raises $200M IPO, advancing next-gen RNAi therapies pipeline, Eli Lilly's oral weight-loss pill Foundayo wins EU regulator backing for obesity and type 2 diabetes
Oct 15, 2026
🧬 Iambic Therapeutics raises $150M IPO, AI-driven drug discovery targeting HER2-positive solid tumors, FDA expands ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) label for high-grade papillary non-muscle invasive bladder cancer, AstraZeneca, Insitro partner on MASH and cardiomyopathy drug discovery, $40M upfront, $1.5B total
Oct 14, 2026
🧬 Zealand Pharma, Generate:Biomedicines partner on AI-designed obesity, metabolic drugs, up to $1.2B deal, Verastem Oncology's (VS-7375) shows 50% objective response rate in Ph1/2 for KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma, Soufflé Therapeutics raises $135M Series A to advance three cell-targeted RNA programs into clinic
Oct 13, 2026
🧬 GSK pledges $800M to build biologics production facility and innovation hub in Pennsylvania, Asahi Kasei's Hovilpri (pritelivir) wins FDA approval for drug-resistant herpes simplex virus lesions in immunocompromised patients following Ph3 success, Roche, Rona Therapeutics license RNAi-based ALK7 obesity candidate for up to $1.16B
Oct 9, 2026
🧬 GSK joins Chai Discovery's AI drug discovery platform following successful wet-lab validation of protein designs, FDA approves Roche's Tecentriq (atezolizumab) for Stage III mismatch repair deficient colon cancer based on Ph3 data, TRex Bio prices $117M IPO to advance immune-regulating Treg-targeted drug pipeline
Oct 8, 2026
🧬 Novartis' Rhapsido (remibrutinib) wins FDA label expansion for symptomatic dermographism based on Ph3 data, Viatris to acquire Pacira BioSciences for $1.65B, expanding non-opioid pain management portfolio, Bristol Myers Squibb's Zenbexus (iberdomide) hits Ph3 progression-free survival endpoint in relapsed or refractory multiple myeloma
Oct 7, 2026
🧬 Cerevance's (solengepras) meets Ph3 primary endpoint, reducing off time in Parkinson's disease, paving path to FDA, Matchpoint Therapeutics raises $150M Series B to advance covalent medicines pipeline into clinic, GSK's Cabenuva (cabotegravir/rilpivirine) shows superior viral suppression in unsuppressed HIV patients in Ph3 trial
Oct 6, 2026
🧬 Shionogi to acquire IntraBio for $2B, gaining rare disease drug Aqneursa approved in two inherited disorders, AbbVie, Genmab's Epkinly (epcoritamab) cuts disease progression risk by 51% in Ph3 first-line diffuse large B cell lymphoma, Forbion raises €2.3B ($2.6B) across two funds to support ~30 high-potential biotechs
Oct 5, 2026
🧬 Bayer invests $2.2B in Ohio manufacturing site to expand U.S. pharma presence, Novartis acquires option on Abogen Biosciences' mRNA-encoded T cell engager, $575M upfront, $7.8B total, Vaxcyte's VAX-31 meets Ph3 endpoints against Pfizer's Prevnar 20 and Merck & Co.'s Capvaxive for pneumococcal disease
Oct 1, 2026
🧬 Sanofi pays Regeneron $1B upfront, up to $7B milestones for four early-stage immunology assets, Eli Lilly shares Ph3 cardiovascular outcomes data for Foundayo (orforglipron) in type 2 diabetes and obesity, Varda raises $251M Series D to manufacture pharmaceuticals in space
Sep 30, 2026
🧬 Roche, Zealand initiate Ph3 program for (petrelintide) in obesity after Ph2 amylin analog shows 9.8% peak weight loss, Eli Lilly shares Ph3 data on (retatrutide), GIP/GLP-1/glucagon triple agonist showing 25% body weight loss in obesity with type 2 diabetes, Pierre Fabre, Atara Biotherapeutics resubmit Ebvallo (tabelecleucel) BLA to FDA for Epstein-Barr virus-positive posttransplant lymphoproliferative disease following Ph3 trial
Sep 29, 2026
🧬 AstraZeneca invests $2B in Summit Therapeutics, gaining 12% equity stake and oncology co-development alliance, Genentech breaks ground on $750M Hillsboro, Oregon manufacturing expansion, doubling facility size by 2031, Novo, Hengrui Pharma partner on weekly oral GLP-1R/GIPR dual agonist for obesity, $300M upfront, up to $2.6B
Sep 28, 2026
🧬 AbbVie's Juvmo (tavapadon) wins FDA approval as first selective D1/D5 receptor agonist for Parkinson's disease, Merck & Co. licenses SciBrunch Therapeutics' preclinical KRAS inhibitor SPR2015, $400M upfront, up to $2.13B total, FDA approves Mirum Pharmaceuticals' Atebrioz (zilurgisertib) targeting ALK2 for fibrodysplasia ossificans progressiva based on Ph2 data
Sep 25, 2026
🧬 Lundbeck to relocate U.S. headquarters to Boston, establishing global innovation hub to expand neuroscience and AI capabilities, Merck & Co., Eisai's Welireg (belzutifan)-Lenvima (lenvatinib) combo wins FDA approval for second-line clear cell renal cell carcinoma after Ph3, Genentech, Earendil Labs partner on AI-driven cancer bispecific antibodies, $55M upfront, $1.5B+ deal
